Research Papers:

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

Christina Krupka, Felix S. Lichtenegger, Thomas Köhnke, Jan Bögeholz, Veit Bücklein, Michael Roiss, Torben Altmann, To Uyen Do, Rachel Dusek, Keith Wilson, Arnima Bisht, Jon Terrett, Dee Aud, Esteban Pombo-Villar, Christian Rohlff, Wolfgang Hiddemann and Marion Subklewe _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:35707-35717. https://doi.org/10.18632/oncotarget.16060

Metrics: PDF 2741 views  |   HTML 3316 views  |   ?  


Christina Krupka1,2,3, Felix S. Lichtenegger1,2,3, Thomas Köhnke1,2,3, Jan Bögeholz4, Veit Bücklein1,2,3, Michael Roiss1,2,3, Torben Altmann1,2,3, To Uyen Do5, Rachel Dusek5, Keith Wilson5,*, Arnima Bisht5, Jon Terrett6,*, Dee Aud6,*, Esteban Pombo-Villar5,*, Christian Rohlff5, Wolfgang Hiddemann1, Marion Subklewe1,2,3

1Department of Internal Medicine III, Klinikum of The LMU Munich, Munich, Germany

2Clinical Cooperation Group Immunotherapy at The Helmholtz Institute Munich, Munich, Germany

3Laboratory of Translational Cancer Immunology, Gene Center Munich, Ludwig-Maximilians-University, Munich, Germany

4Department of Hematology, University Hospital Zurich, Zurich, Switzerland

5Independent consultant Oxford BioTherapeutics Ltd, Abingdon, United Kingdom and San Jose, CA, USA

6CRISPR Therapeutics, Cambridge, MA, USA

*Were employed at Oxford Biotherapeutics at the time the data was generated

Correspondence to:

Subklewe Marion, email: [email protected]

Keywords: AML, Immunotherapy, CD157, Antibody, Fc-engineering

Received: November 01, 2016     Accepted: February 27, 2017     Published: March 09, 2017


Antibody-based immunotherapy represents a promising strategy to eliminate chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated a novel Fc-engineered antibody against CD157 (MEN1112) for its suitability as immunotherapy in AML. CD157 was expressed in 97% of primary AML patient samples. A significant, albeit lower expression level of CD157 was observed within the compartment of leukemia-initiating cells, which are supposed to be the major source of relapse. In healthy donor bone marrow, CD157 was expressed on CD34+ cells. In ex vivo assays, MEN1112 triggered natural killer (NK) cell-mediated cytotoxicity against AML cell lines and primary AML cells. Compared to its parental analogue, the Fc-engineered antibody exhibited higher antibody dependent cellular cytotoxicity responses. Using NK cells from AML patients, we observed heterogeneous MEN1112-mediated cytotoxicity against AML cells, most likely due to well-documented defects in AML-NK cells and corresponding inter-patient variations in NK cell function. Cytotoxicity could not be correlated to the time after completion of chemotherapy. In summary, we could demonstrate that CD157 is strongly expressed in AML. MEN1112 is a promising antibody construct that showed high cytotoxicity against AML cells and warrants further clinical testing. Due to variability in NK-cell function of AML patients, the time of application during the course of the disease as well as combinatorial strategies might influence treatment results.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16060